Aixindawei Pharmaceutical Overview
- Year Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
PE Growth
- Investors
-
15
Aixindawei Pharmaceutical General Information
Description
Developer of small-molecule drug conjugates intended to treat advanced malignant solid neoplasms and hematological cancers. The company provides technology that utilizes aldo-keto reductase family 1 member C3 (AKR1C3) enzyme activation and hypoxia-activated prodrug platforms to develop targeted therapies, including AST-3424, AST-001, AST-002, AST-003, AST-004, and AST-007, enabling the oncology sector to access selective, intracellularly activated treatments for treatment-resistant tumors.
Contact Information
Website
www.ascentawits.comCorporate Office
- Building 12, Biomedical Innovation Industrial Park
- Number 14 Jinhui Road, Pingshan District
- Shenzhen, Guangdong
- China
Corporate Office
- Building 12, Biomedical Innovation Industrial Park
- Number 14 Jinhui Road, Pingshan District
- Shenzhen, Guangdong
- China
Aixindawei Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. PE Growth/Expansion | Completed | Generating Revenue | ||||
| 10. Secondary Transaction - Private | 07-May-2026 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series C) | 06-May-2026 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Private | 28-Mar-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B1) | 27-Mar-2023 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B) | 15-Nov-2022 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 09-Feb-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A1) | 06-Nov-2019 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 08-Jul-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 23-Apr-2018 | Completed | Generating Revenue |
Aixindawei Pharmaceutical Patents
Aixindawei Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026201124-A1 | Method for treating cancer with ast-001 and use thereof in preparing medicament for treating cancer | Pending | 28-Mar-2025 | ||
| WO-2026179849-A1 | Ast-3424 metabolite and use | Pending | 25-Feb-2025 | ||
| WO-2026166538-A1 | Lyophilized preparation solution of ast-3424, lyophilized preparation, method, and use | Pending | 10-Feb-2025 | ||
| WO-2026149530-A1 | Treatment of cancer and tumor patients with mutations in fanc gene, xrcc gene, or atm gene | Pending | 09-Jan-2025 | ||
| WO-2026145755-A1 | Method for treating patients with drug tolerance by akr1c3 enzyme-activated compound | Pending | 03-Jan-2025 |
Aixindawei Pharmaceutical Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Fosun Health Capital | Corporate Venture Capital | Minority | ||
| Fosun Pharma | Corporation | Minority | ||
| Changna Investment | Growth/Expansion | Minority | ||
| Hunan Salt Industry Group | Corporation | Minority | ||
| China Capital Management | PE/Buyout | Minority |
Aixindawei Pharmaceutical FAQs
-
When was Aixindawei Pharmaceutical founded?
Aixindawei Pharmaceutical was founded in 2014.
-
Where is Aixindawei Pharmaceutical headquartered?
Aixindawei Pharmaceutical is headquartered in Shenzhen, China.
-
What industry is Aixindawei Pharmaceutical in?
Aixindawei Pharmaceutical’s primary industry is Drug Discovery.
-
Is Aixindawei Pharmaceutical a private or public company?
Aixindawei Pharmaceutical is a Private company.
-
What is Aixindawei Pharmaceutical’s current revenue?
The current revenue for Aixindawei Pharmaceutical is .
-
How much funding has Aixindawei Pharmaceutical raised over time?
Aixindawei Pharmaceutical has raised $32.3M.
-
Who are Aixindawei Pharmaceutical’s investors?
Fosun Health Capital, Fosun Pharma, Changna Investment, Hunan Salt Industry Group, and China Capital Management are 5 of 15 investors who have invested in Aixindawei Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process